One or two intact local summaries. No averaged regimen, patient-specific dose or automatic source preference.
1 local source card selected. Local card fingerprints checked where supplied. This is not an original-document hash, source-currency guarantee or clinical approval. Record-level cautions below are the current library's cautions, not a frozen prior version.
Independent clinical review is pending. Confirm indication, exact formulation/route, population, renal measure and units, kidney-function stability, dialysis prescription, interacting drugs, monitoring and source revision. An RX mirror and its original label are not independent corroboration. Missing disagreement notes do not certify agreement.
Adult 450 mg tablet source. No pediatric solution or institutional HD regimen is inferred.
The VALCYTE label provides no adult tablet dose for hemodialysis and says those tablets should not be used. UCSF lists institutional oral treatment and prophylaxis schedules in intermittent HD. This is a real label-versus-institution difference, not two independently agreeing labels.
What to reconcile: Confirm CMV indication, transplant context, formulation, dialysis schedule, cytopenias and infectious-disease input. The institutional regimen is not labeled approval; IV ganciclovir is preferred by UCSF for initiation in unstable renal function or dialysis.
Open this note and its source referencesUCSF lists prophylaxis every 48 hours during continuous HD. The Jarrell primary abstract studied daily enteral dosing in ten ICU transplant recipients on CVVHD and found that most reached a proposed trough target. These sources differ, but the study is not a comparative clinical-outcomes trial.
What to reconcile: Reconcile the actual dialysis modality and clearance, absorption, CMV risk, counts and monitoring. Full-text flow-rate details were not reviewed; no universal CRRT dose is derived or automatically preferred.
Open this note and its source referencesFor CrCl >=60, induction is 900 mg twice daily and maintenance/prevention 900 mg daily. At 40-59, use 450 mg twice daily or 450 mg daily, respectively. At 25-39, use 450 mg daily or every two days. At 10-24, use 450 mg every two days or twice weekly. Below 10 on hemodialysis, the label provides no tablet dose and says the tablets should not be used; it directs clinicians to appropriately adjusted ganciclovir. Monitor kidney function and blood counts. Take with food and do not crush or split tablets. Institutional dialysis regimens are displayed separately, not called label-approved.
RDM40-official-valganciclovir-5fe607ba2e-C1 · Source locator: Sections 2.1, 2.5 (Table 2), 2.6, 5.1 and 8.6
This reference does not select a regimen. Complete the indication, measured/estimated renal function and trend, dialysis setting, source rationale, monitoring and reassessment plan in your institution's approved documentation system. Confirm the complete current source before adopting its regimen.
Pinned reference: https://globalrph.com/blogCalcs/renal-dosing-master/compare.php?id=valganciclovir&s1=RDM40-official-valganciclovir-5fe607ba2e&h1=4a598d16dec1847520279b8b5dea7658dd2777199f6368dff2798498c429d823